Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 10/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22581128 | 1.00 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129495 | 0.96 | IKZF2 (0.55) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129758 | 0.93 | IKZF2 (0.56) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL20234415 | 0.92 | CRBN (0.51) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL22581089 | 0.92 | IKZF2 (0.56) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129754 | 0.89 | CRBN (0.52) | IKZF1CRBNIKZF3DDB1BRD4 | |
| SCHEMBL22581115 | 0.88 | CRBN (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL22581112 | 0.88 | CRBN (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129343 | 0.86 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129506 | 0.86 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485735-B2 | Selective CDK4/6 inhibitor and preparation thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485735-B2 | Selective CDK4/6 inhibitor and preparation thereof | CDK4, CDK6, CDK3 | IKZF2 1839/4885IKZF1 1337/4885CRBN 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.